Medtronic is working with New England hospitals and government health officials to track the movement of surgical medical equipment involved in several cases of possible patient exposure to Creutzfeldt-Jakob disease, a rare and fatal relative to the more commonly known "mad cow" disease.
The law that has helped medical discoveries make the leap from university labs to the marketplace for more than 30 years needs revising, in part to ensure the American people benefit from science their tax dollars have paid for, says a University of Michigan Medical School physician and medical historian.
Despite widespread adoption by hospitals of surgical robot technology over the past decade, a “slapdash” system of reporting complications paints an unclear picture of its safety, according to Johns Hopkins researchers. In a report published online in the Journal for Healthcare Quality...
Pure cardiac muscle cells, ready to transplant into a patient affected by heart disease. That’s a goal for many cardiology researchers working with stem cells. Having a pure population of cardiac muscle cells is essential for avoiding tumor formation after transplantation, but has been technically challenging.
The lightweight skeletons of organisms such as sea sponges display a strength that far exceeds that of manmade products constructed from similar materials. Scientists have long suspected that the difference has to do with the hierarchical architecture of the biological materials...
Four patients in Kuala Lumpur, Malaysia were successfully treated with CardioKinetix's catheter-based Parachute ventricular partitioning device, the Menlo Park, Calif.-based firm announced late last month. The Parachute device is a minimally invasive catheter-based treatment which separates damaged heart muscle from healthy tissue...
New companies tend to decide pretty early on whether to build medical affairs teams separate from their commercial operations, a decision that may hold implications for later compliance concerns. More than half of the companies surveyed by Cutting Edge Information chose to define centralized medical affairs teams, noting it as a top concern early in their organization.
Enzymatics, Inc., a leading producer of reagents, kits, and assays, today announced it has acquired Boulder-based ArcherDx, Inc., a developer of innovative, NGS-based kits and software solutions for use in investigating cancer treatment. The deal consists of cash, equity and potential milestones worth up to $50 million.
Trovagene, Inc., a developer of molecular diagnostics for cancer monitoring, today announced that the Company has entered into a clinical collaboration agreement with the University of Southern California to study genomic characterizations of metastatic colorectal cancers using Trovagene's proprietary cell-free DNA assays.
A lean initiatives program, undertaken over a period of years to improve quality and on-time delivery, has been a boon to the company’s ability to meet medical device makers’ needs. About three years ago, the company refocused its ongoing lean manufacturing initiatives to take aim at improving the company’s bottom line by eliminating waste while improving quality and delivery.
In order to reduce unneeded animal testing and possible cost and duration of testing, the ISO 10993 committee is looking to add an in vitro option to irritation testing. For the past 20 years, if you wanted to test for irritation, you had to do a version of the animal irritation test.
The new Legato 110 Dual Rate Syringe Pump System (Legato 110 DRS) offers researchers complete flexibility to start two pumps simultaneously for delivery of two independent flow rates. The pumps are synchronized through a special input/output cable included with the system.
California spinal devices maker NuVasive Inc. has recently gotten very popular with law firms, which began piling onto a class action lawsuit following the revelation that the company is under investigation by the Health & Human Services Dept.'s Office of the Inspector General.
Associated Power Technologies (APT) announced the release of their 400XAC Series of three phase AC power sources. The 400XAC product family was designed as a versatile, three phase power source with two standard models: the 430XAC (3kVA source) and the 460XAC (6kVA source).
FDA regulators put their highest-risk Class I label on Siemens' (NYSE:SI) recall of more than 78,000 of its MicroScan Synergies plus and MicroScan rapID/S plus antimicrobial tests, warning that false test results could hinder patient care.